WaveMan
WaveMan · Company
ALLO · Allogene Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ALLO Allogene Therapeutics (ALLO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001737287
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
131
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced

What the filings say about ALLO

Insiders, 180 days
-$111.7K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$111.7K
2 notices

Allogene Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Allogene Therapeutics, Inc. insiders sold a net $111.7K of stock across 61 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Parker Geoffrey M.
CHIEF FINANCIAL OFFICER
SELL
2026-10-23 SECtraded 2026-10-21
36,342
$48.7K
+1.7%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Feb 2, 2026.
  • The trade is 3.5% of the 1,045,877 shares held after it.
  • No other insider sold within 30 days.
  • 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Parker Geoffrey M. sold about $48.7K of ALLO on Oct 21, 2026; 131 funds added in the latest 13F quarter.
Douglas Earl Martin
SVP, General Counsel
SELL
2026-08-25 SECtraded 2026-08-21
29,697
$63.0K
-39.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 2, 2026.
  • The trade is 6.1% of the 488,267 shares held after it.
  • No other insider sold within 30 days.
  • 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, General Counsel Douglas Earl Martin sold about $63.0K of ALLO on Aug 21, 2026; 131 funds added in the latest 13F quarter.
Yoshiyama Annie
SVP, Finance
SELL
2026-04-23 SECtraded 2026-04-21
9,586
$22.1K
-46.8%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 2, 2026.
  • The trade is 7.7% of the 124,517 shares held after it.
  • 1 other insider sold within 30 days.
  • 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Finance Yoshiyama Annie sold about $22.1K of ALLO on Apr 21, 2026; 1 other insider sold within 30 days and 131 funds added in the latest 13F quarter.
Beneski Benjamin Machinas
SVP, Chief Technical Officer
SELL
2026-04-02 SECtraded 2026-03-31
2,867
$7.2K
-52.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 16, 2026.
  • The trade is 1.5% of the 195,338 shares held after it.
  • 2 other insiders sold within 30 days.
  • 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Technical Officer Beneski Benjamin Machinas sold about $7.2K of ALLO on Mar 31, 2026; 2 other insiders sold within 30 days and 131 funds added in the latest 13F quarter.
Beneski Benjamin Machinas
SVP, Chief Technical Officer
SELL
2026-03-18 SECtraded 2026-03-16
4,835
$11.9K
-44.6%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 2, 2026.
  • The trade is 2.4% of the 198,205 shares held after it.
  • 1 other insider sold within 30 days.
  • 131 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Technical Officer Beneski Benjamin Machinas sold about $11.9K of ALLO on Mar 16, 2026; 1 other insider sold within 30 days and 131 funds added in the latest 13F quarter.
61 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 56 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$111.7K over 180 days
-$111.7K over 90 days
more than 55% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
131 funds bought in last quarter
more than 78% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.9% of the float short (float per yahoo 2026-10-27) · 9.2 days to cover · settled 2026-10-15
more than 86% of Pharma & Biotech
What changed in the last 30 days
Oct 23CHIEF FINANCIAL OFFICER Parker Geoffrey M. sold $48.7K (Oct 21)
Oct 21Officer Parker Geoffrey M. filed to sell $48.7K by Oct 21 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ALLO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.7%12M
-13%+42%+98%+153%2025-102025-122026-022026-042026-062026-082026-10 2026-02-02 · Chang David D sold $171.5K2026-03-16 · Chang David D sold $118.0K2026-02-02 · Roberts Zachary sold $63.2K2026-08-21 · Douglas Earl Martin sold $63.0K2026-10-21 · Parker Geoffrey M. sold $48.7K2026-02-02 · Parker Geoffrey M. sold $42.2K2026-01-21 · Roberts Zachary sold $41.0K2026-02-02 · Douglas Earl Martin sold $40.3K2026-04-21 · Yoshiyama Annie sold $22.1K2026-03-02 · Beneski Benjamin Machinas sold $18.5K2026-02-02 · Beneski Benjamin Machinas sold $13.1K2026-03-16 · Beneski Benjamin Machinas sold $11.9K2026-03-31 · Beneski Benjamin Machinas sold $7.2K2026-02-02 · Yoshiyama Annie sold $7.2K2025-11-17 · Beneski Benjamin Machinas sold $9592026-10-21 · Parker Geoffrey M. filed to sell $48.7K2026-08-21 · Douglas Earl Martin filed to sell $63.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ALLO: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
30,146,963 sh
$62.7M
Pfizer Inc
22,032,040 sh
$46.9M
Frazier Life Sciences Management, L.P.
22,446,668 sh
$46.7M
STATE STREET CORP
19,025,826 sh
$39.6M
TPG GP A, LLC
18,716,306 sh
$38.9M

Congress trades in ALLO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ALLO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Parker Geoffrey M.
Filed 2026-10-21
$48.7K
Douglas Earl Martin
Filed 2026-08-21
$63.0K

ALLO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$307.5K position · as of 2026-07-31
0.7%
Select Biotechnology Portfolio
$20.7M position · as of 2026-05-31
0.4%
Ultra-Small Company Market Fund
$520.0K position · as of 2026-06-30
0.4%
Invesco NASDAQ Future Gen 200 ETF
$60.0K position · as of 2026-05-31
0.3%
NVIT Small Cap Value Fund
$577.9K position · as of 2026-06-30
0.3%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$25.3M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
2 active
2
Phase 2
1 active
1
Not applicable
1 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Chang
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.1M
$1.9M
$2.3M
-78%
n/a
2024
$4.5M
$872.4K
$2.0M
-66%
n/a
2023
$14.1M
$1.3M
$7.0M
-49%
n/a
2022
$14.8M
$1.4M
$5.0M
-58%
n/a
2021
$10.2M
-$2.3M
$5.0M
-42%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $111.7K sold by insiders over 180 days, 131 funds added last quarter, $111.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ALLO financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$102.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-42.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-32.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-37.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-24.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122023-09
Revenue$0$22.0K$95.0Kn/a
Operating income-$209.3M-$273.2M-$327.7Mn/a
Net income-$190.9M-$257.6M-$327.3Mn/a
EPS (diluted)-0.87-1.32-2.09n/a
Operating cash flow-$149.2M-$200.3M-$237.7Mn/a
Cash$51.7M$75.2M$83.2M$69.2M
SEC XBRL, fiscal years, as known on 2026-10-28

ALLO Stock Sonar score 5/7 axes

Find similar shapesCompare

ALLO ranks highest on institutional and government (78th percentile) and profitability (60th), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
60
Inputs
  • Return on equity-42.4% · 59 pct, sector of 545
  • Return on assets-32.4% · 58 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-37.7% · 62 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
26
Inputs
  • Net Form 4 buying (codes P and S), 180d-$112K · 53 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
78
Inputs
  • Funds adding, latest quarter131 · 78 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
24
Inputs
  • Short interest, % of float+18.9% · 16 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+14.2% · 32 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ALLO filings, in plain words

Are Allogene Therapeutics insiders buying or selling ALLO?

In the 180 days to 2026-10-28, Allogene Therapeutics insiders were net sellers, a net $111.7K across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of ALLO?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $111.7K of stock; the latest, by Parker Geoffrey M., was filed 2026-10-21.

Read the full summary

In the 180 days to 2026-10-28, Allogene Therapeutics insiders were net sellers of ALLO, a net $111.7K across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $111.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies